KalVista Pharmaceuticals, Inc. News Releases http://ir.kalvista.com/ KalVista Pharmaceuticals, Inc. News Releases en KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology http://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-presents-kvd900-data-european-academy – KVD900 Demonstrates Rapid and Nearly Complete Suppression of Plasma Kallikrein Activity in a Phase 1 Study – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 4, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, Tue, 04 Jun 2019 07:30:00 -0400 KalVista Pharmaceuticals, Inc. News Releases 8216 KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference http://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-present-jefferies-healthcare-1 CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 30, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at Thu, 30 May 2019 07:30:00 -0400 KalVista Pharmaceuticals, Inc. News Releases 8211 KalVista Pharmaceuticals Presents KVD900 Data at C1-Inhibitor Deficiency and Angioedema Workshop http://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-presents-kvd900-data-c1-inhibitor – KVD900 Phase 1 Data Show Rapid Suppression of Plasma Kallikrein Activity and is Well Tolerated for Potential Use as On-Demand Treatment for HAE – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 28, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical Tue, 28 May 2019 07:30:00 -0400 KalVista Pharmaceuticals, Inc. News Releases 8201 KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences http://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-present-data-upcoming-scientific – Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 20, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the Mon, 20 May 2019 07:30:00 -0400 KalVista Pharmaceuticals, Inc. News Releases 8196 KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019 http://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-presents-data-association-research-0 – Novel Oral Plasma Kallikrein Inhibitors KV998052 and KV998054 Prevent and Reverse VEGF-Induced Retinal Edema in Mice – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 30, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the Tue, 30 Apr 2019 07:30:00 -0400 KalVista Pharmaceuticals, Inc. News Releases 8166 KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors http://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-appoints-daniel-b-soland-board CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 22, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has Mon, 22 Apr 2019 07:30:00 -0400 KalVista Pharmaceuticals, Inc. News Releases 8126 KalVista Pharmaceuticals to Present at Needham Healthcare Conference http://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-present-needham-healthcare-conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 3, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at Wed, 03 Apr 2019 07:30:00 -0400 KalVista Pharmaceuticals, Inc. News Releases 8081 KalVista Pharmaceuticals Announces the Promotion of Benjamin L. Palleiko to Include Chief Business Officer http://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-promotion-benjamin-l-palleiko CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 27, 2019-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the promotion of Ben Wed, 27 Mar 2019 07:30:00 -0400 KalVista Pharmaceuticals, Inc. News Releases 8056 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results http://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-1 – Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosing in First-in-Human Trial – CAMBRIDGE, Mass. Thu, 14 Mar 2019 07:30:00 -0400 KalVista Pharmaceuticals, Inc. News Releases 8006 KalVista Pharmaceuticals Presents Data at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019 http://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-presents-data-american-academy-allergy – KVD900 600 mg Provides >90% Inhibition of Plasma Kallikrein Within 30 Minutes of Dosing – – Single 600 mg Dose of KVD900 Provides Protection of HK Cleavage for at Least 10 Hours – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 25, 2019-- KalVista Pharmaceuticals, Inc. Mon, 25 Feb 2019 07:30:00 -0500 KalVista Pharmaceuticals, Inc. News Releases 7991